Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group

被引：37

作者：

Kreissl, Stefanie ^{[1
]}

Mueller, Horst ^{[1
]}

Goergen, Helen ^{[1
]}

Meissner, Julia ^{[2
]}

Topp, Max ^{[3
]}

Soekler, Martin ^{[4
]}

Markova, Jana ^{[5
,6
]}

Bernhard, Jurg ^{[7
,13
]}

Greil, Richard ^{[8
,9
]}

von Tresckow, Bastian ^{[1
]}

Behringer, Karolin ^{[1
]}

Rueffer, Jens-Ulrich ^{[10
]}

Flechtner, Hans-Henning ^{[11
]}

Moestl, Michaela ^{[12
]}

Fuchs, Michael ^{[1
]}

Engert, Andreas ^{[1
]}

Diehl, Volker ^{[1
]}

Borchmann, Peter ^{[1
]}

机构：

[1] Univ Cologne, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Dept Internal Med 1, German Hodgkin Study Grp, Cologne, Germany

[2] Heidelberg Univ, Heidelberg, Germany

[3] Univ Hosp Wurzburg, Wurzburg, Germany

[4] Univ Hosp Tubingen, Hematol Oncol, Tubingen, Germany

[5] Charles Univ Prague, Prague, Czech Republic

[6] Fac Hosp Kralovske Vinohrady, Prague, Czech Republic

[7] Univ Bern, Bern Univ Hosp, Dept Oncol, Inselspital, Bern, Switzerland

[8] Paracelsus Med Univ, Canc Res Inst, Med Dept 3, Salzburg, Austria

[9] Arbeitsgemeinschaft Medikamentose Tumortherapie, Salzburg, Austria

[10] German Fatigue Soc, Cologne, Germany

[11] Otto von Guericke Univ, Dept Child & Adolescent Psychiat & Psychotherapy, Magdeburg, Germany

[12] Hanusch Hosp, Med Dept 3, Vienna, Austria

[13] Swiss Grp Clin Canc Res, Bern, Switzerland

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 25期

关键词：

CANCER-RELATED FATIGUE; OPEN-LABEL; DISEASE SURVIVORS; QLQ-C30; TRIAL;

D O I：

10.1200/JCO.19.03160

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSE Many important details of health-related quality of life (HRQoL) after diagnosis and treatment of Hodgkin lymphoma (HL) are still unknown because large longitudinal studies of HRQoL are rare. Therefore, we analyzed a systematically assessed, comprehensive range of HRQoL domains in patients with HL of all stages from diagnosis up to 5 years of survivorship. PATIENTS AND METHODS We included patients with HL age 18-60 years at diagnosis from the German Hodgkin Study Group trials HD13, HD14, and HD15. We analyzed HRQoL using all functional and symptom scales of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 including deviations from reference values. We estimated the effect of different disease, patient, and treatment characteristics using multiple regression and repeated measures analysis and computed correlations of HRQoL scores. RESULTS We analyzed 4,215 patients with any HRQoL assessment within 5 years after treatment. Higher tumor burden at diagnosis was associated with impaired baseline scores in many HRQoL domains. During survivorship, cognitive, emotional, role, and social functioning and fatigue, dyspnea, sleep, and financial problems were severely and persistently affected. From year 2 on, mean deviations from reference values ranged between 12 and 29 points, with 10 points being a commonly used margin of clinical relevance. In all 3 trials, HRQoL domains 2 and 5 years after therapy were significantly influenced by baseline scores and age but not by randomized treatments. Fatigue was most closely correlated with other symptoms and scales. CONCLUSION Our results show a high and persistent amount of different HRQoL deficits in survivors of HL that are largely independent of the applied chemotherapies. Our analysis underscores the high, unmet medical need of these rather young survivors of HL regarding the psychosocial adverse effects of the cancer experience.

引用

页码：2839 / +

页数：18

共 20 条

[1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].

AARONSON, NK ;

AHMEDZAI, S ;

BERGMAN, B ;

BULLINGER, M ;

CULL, A ;

DUEZ, NJ ;

FILIBERTI, A ;

FLECHTNER, H ;

FLEISHMAN, SB ;

DEHAES, JCJM ;

KAASA, S ;

KLEE, M ;

OSOBA, D ;

RAZAVI, D ;

ROFE, PB ;

SCHRAUB, S ;

SNEEUW, K ;

SULLIVAN, M ;

TAKEDA, F .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376

[2]

[Anonymous], 1946, CONST WHO

[3] Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration [J].

Behringer, Karolin ;

Goergen, Helen ;

Mueller, Horst ;

Thielen, Indra ;

Brillant, Corinne ;

Kreissl, Stefanie ;

Halbsguth, Teresa Veronika ;

Meissner, Julia ;

Greil, Richard ;

Moosmann, Peter ;

Shonukan, Oluwatoyin ;

Rueffer, Jens Ulrich ;

Flechtner, Hans-Henning ;

Fuchs, Michael ;

Diehl, Volker ;

Engert, Andreas ;

Borchmann, Peter .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (36) :4329-+

[4] Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial [J].

Behringer, Karolin ;

Goergen, Helen ;

Hitz, Felicitas ;

Zijlstra, Josee M. ;

Greil, Richard ;

Markova, Jana ;

Sasse, Stephanie ;

Fuchs, Michael ;

Topp, Max S. ;

Soekler, Martin ;

Mathas, Stephan ;

Meissner, Julia ;

Wilhelm, Martin ;

Koch, Peter ;

Lindemann, Hans-Walter ;

Schalk, Enrico ;

Semrau, Robert ;

Kriz, Jan ;

Vieler, Tom ;

Bentz, Martin ;

Lange, Elisabeth ;

Mahlberg, Rolf ;

Hassler, Andre ;

Vogelhuber, Martin ;

Hahn, Dennis ;

Mezger, Joerg ;

Krause, Stefan W. ;

Skoetz, Nicole ;

Boell, Boris ;

von Tresckow, Bastian ;

Diehl, Volker ;

Hallek, Michael ;

Borchmann, Peter ;

Stein, Harald ;

Eich, Hans ;

Engert, Andreas .

LANCET, 2015, 385 (9976) :1418-1427

[5] PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group [J].

Borchmann, Peter ;

Goergen, Helen ;

Kobe, Carsten ;

Lohri, Andreas ;

Greil, Richard ;

Eichenauer, Dennis A. ;

Zijlstra, Josee M. ;

Markova, Jana ;

Meissner, Julia ;

Feuring-Buske, Michaela ;

Huttmann, Andreas ;

Dierlamm, Judith ;

Soekler, Martin ;

Beck, Hans-Joachim ;

Willenbacher, Wolfgang ;

Ludwig, Wolf-Dieter ;

Pabst, Thomas ;

Topp, Max S. ;

Hitz, Felicitas ;

Bentz, Martin ;

Keller, Ulrich Bernd ;

Kuhnhardt, Dagmar ;

Ostermann, Helmut ;

Schmitz, Norbert ;

Hertenstein, Bernd ;

Aulitzky, Walter ;

Maschmeyer, Georg ;

Vieler, Tom ;

Eich, Hans ;

Baues, Christian ;

Stein, Harald ;

Fuchs, Michael ;

Kuhnert, Georg ;

Diehl, Volker ;

Dietlein, Markus ;

Engert, Andreas .

LANCET, 2017, 390 (10114) :2790-2802

[6] Quality of life in long-term survivors following treatment for Hodgkin's disease during childhood and adolescence in the German multicentre studies between 1978 and 2002 [J].

Calaminus, Gabriele ;

Doerffel, Wolfgang ;

Baust, Katja ;

Teske, Carmen ;

Riepenhausen, Marianne ;

Braemswig, Juergen ;

Flechtner, Hans-Henning ;

Singer, Susanne ;

Hinz, Andreas ;

Schellong, Guenther .

SUPPORTIVE CARE IN CANCER, 2014, 22 (06) :1519-1529

[7] Evidence-Based Guidelines for Determination of Sample Size and Interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 [J].

Cocks, Kim ;

King, Madeleine T. ;

Velikova, Galina ;

St-James, Marrissa Martyn ;

Fayers, Peter M. ;

Brown, Julia M. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (01) :89-96

[8] Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial [J].

Engert, Andreas ;

Haverkamp, Heinz ;

Kobe, Carsten ;

Markova, Jana ;

Renner, Christoph ;

Ho, Antony ;

Zijlstra, Josee ;

Kral, Zdenek ;

Fuchs, Michael ;

Hallek, Michael ;

Kanz, Lothar ;

Doehner, Hartmut ;

Doerken, Bernd ;

Engel, Nicole ;

Topp, Max ;

Klutmann, Susanne ;

Amthauer, Holger ;

Bockisch, Andreas ;

Kluge, Regine ;

Kratochwil, Clemens ;

Schober, Otmar ;

Greil, Richard ;

Andreesen, Reinhard ;

Kneba, Michael ;

Pfreundschuh, Michael ;

Stein, Harald ;

Eich, Hans Theodor ;

Mueller, Rolf-Peter ;

Dietlein, Markus ;

Borchmann, Peter ;

Diehl, Volker .

LANCET, 2012, 379 (9828) :1791-1799

[9] Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group study 9133 [J].

Ganz, PA ;

Moinpour, CM ;

Pauler, DK ;

Kornblith, AB ;

Gaynor, ER ;

Balcerzak, SP ;

Gatti, GS ;

Erba, HP ;

McCoy, S ;

Press, OW ;

Fisher, RI .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (18) :3512-3519

[10] Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial [J].

Heutte, Natacha ;

Flechtner, Henning H. ;

Mounier, Nicolas ;

Mellink, Wilhelmina A. M. ;

Meerwaldt, Jacobus H. ;

Eghbali, Houchingue ;

van't Veer, Mars B. ;

Noordijk, Evert M. ;

Kluin-Nelemans, Johanna C. ;

Lampka, Elzbieta ;

Thomas, Jose ;

Lugtenburg, Pieternella J. ;

Viterbo, Luisa ;

Carde, Patrice ;

Hagenbeek, Anton ;

van der Maazen, Richard W. M. ;

Smit, Wilma G. J. M. ;

Brice, Pauline ;

Kooy, Marinus van Marwijk ;

Baars, Johanna W. ;

Poortmans, Philip ;

Tirelli, Umberto ;

Leeksma, Onno C. ;

Tomsic, Radka ;

Feugier, Pierre ;

Salles, Gilles ;

Gabarre, Jean ;

Kersten, Marie Jose ;

Van Den Neste, Eric ;

Creemers, Geert-Jan M. ;

Gaillard, Isabelle ;

Meijnders, Paul ;

Tertian, Gerard ;

Reman, Oumedaly ;

Muller, Hein P. ;

Troncy, Jacques ;

Blanc, Michel ;

Schroyens, Wilfried ;

Voogt, Paul J. ;

Wijermans, Pierre ;

Rieux, Chantal ;

Ferme, Christophe ;

Henry-Amar, Michel .

LANCET ONCOLOGY, 2009, 10 (12) :1160-1170

← 1 2 →